ASX:KZA

Stock Analysis Report

Executive Summary

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops therapies for a range of oncology indications.

Snowflake

Fundamentals

Adequate balance sheet and overvalued.

Risks

  • Kazia Therapeutics has significant price volatility in the past 3 months.
  • Kazia Therapeutics is covered by less than 3 analysts.

Share Price & News

How has Kazia Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

26.3%

KZA

1.7%

AU Biotechs

1.0%

AU Market


1 Year Return

18.8%

KZA

15.3%

AU Biotechs

7.2%

AU Market

KZA outperformed the Biotechs industry which returned 15.3% over the past year.

KZA outperformed the Market in Australia which returned 7.2% over the past year.


Share holder returns

KZAIndustryMarket
7 Day26.3%1.7%1.0%
30 Day44.3%1.2%3.2%
90 Day57.8%11.3%1.4%
1 Year18.8%18.8%16.7%15.3%13.4%7.2%
3 Year-49.5%-49.5%133.2%124.8%40.7%21.8%
5 Year-62.3%-62.6%211.7%191.6%50.8%17.0%

Price Volatility Vs. Market

How volatile is Kazia Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Kazia Therapeutics undervalued based on future cash flows and its price relative to the stock market?

2.21x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Kazia Therapeutics to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Kazia Therapeutics to establish if it is available at substantial discount.


Price Based on Earnings

Kazia Therapeutics is loss making, we can't compare its value to the Global Biotechs industry average.

Kazia Therapeutics is loss making, we can't compare the value of its earnings to the Australia market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Kazia Therapeutics, we can't assess if its growth is good value.


Price Based on Value of Assets

Kazia Therapeutics is good value based on assets compared to the AU Biotechs industry average.


Next Steps

Future Growth

How is Kazia Therapeutics expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

-8.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Kazia Therapeutics's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.

Kazia Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.

Kazia Therapeutics's revenues are expected to decrease over the next 1-3 years, this is below the Australia market average.

Unable to compare Kazia Therapeutics's earnings growth to the Australia market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Kazia Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Kazia Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Kazia Therapeutics performed over the past 5 years?

-5.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Kazia Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Kazia Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Kazia Therapeutics's 1-year growth to the Global Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Kazia Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Kazia Therapeutics has efficiently used its assets last year compared to the Global Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Kazia Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Kazia Therapeutics's financial position?


Financial Position Analysis

Kazia Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Kazia Therapeutics's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Kazia Therapeutics has no debt.

Kazia Therapeutics has no debt compared to 5 years ago when it was 181.6%.


Balance Sheet

Low level of unsold assets.

Kazia Therapeutics has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Kazia Therapeutics has less than a year of cash runway based on current free cash flow.

Kazia Therapeutics has less than a year of cash runway if free cash flow continues to reduce at historical rates of -25.6% each year.


Next Steps

Dividend

What is Kazia Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Kazia Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Kazia Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Kazia Therapeutics has not reported any payouts.

Unable to verify if Kazia Therapeutics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Kazia Therapeutics has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Kazia Therapeutics's dividends in 3 years as they are not expected to pay a notable one for Australia.


Next Steps

Management

What is the CEO of Kazia Therapeutics's salary, the management and board of directors tenure and is there insider trading?

3.0yrs

Average management tenure


CEO

James Garner (46yo)

3.6yrs

Tenure

AU$691,085

Compensation

Dr. James Garner, MA, MBA, MBBS, BSC (Hons), MAICD, has been the Chief Executive Officer, Managing Director and Executive Director of Kazia Therapeutics Limited (formerly Novogen Limited) since February 1, ...


CEO Compensation Analysis

James's remuneration is higher than average for companies of similar size in Australia.

James's compensation has increased whilst company is loss making.


Management Age and Tenure

3.0yrs

Average Tenure

The tenure for the Kazia Therapeutics management team is about average.


Board Age and Tenure

3.0yrs

Average Tenure

65yo

Average Age

The tenure for the Kazia Therapeutics board of directors is about average.


Insider Trading

More shares have been bought than sold by Kazia Therapeutics individual insiders in the past 3 months.


Recent Insider Transactions

BuyAU$3,77104 Sep 19
James Garner
EntityIndividual
Role
Chief Executive Officer
CEO, MD & Executive Director
Shares10,000
Max PriceAU$0.38
BuyAU$20,84509 Jul 19
Hishenk Pty Ltd.
EntityCompany
Shares55,000
Max PriceAU$0.38
BuyAU$19,85203 Jul 19
Steven Coffey
EntityIndividual
Role
Member of the Board of Directors
Independent Non-Executive Director
Shares60,000
Max PriceAU$0.33
BuyAU$19,85203 Jul 19
Bryce Carmine
EntityIndividual
Role
Member of the Board of Directors
Independent Non-Executive Director
Shares60,000
Max PriceAU$0.33
BuyAU$21,50703 Jul 19
James Garner
EntityIndividual
Role
Chief Executive Officer
CEO, MD & Executive Director
Shares65,000
Max PriceAU$0.33
BuyAU$41,35903 Jul 19
Iain Ross
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares125,000
Max PriceAU$0.33
SellAU$3,42003 Jul 19
Hishenk Pty Ltd.
EntityCompany
Shares9,000
Max PriceAU$0.38
BuyAU$301,46803 Jul 19
Hishenk Pty Ltd.
EntityCompany
Shares662,981
Max PriceAU$0.45
BuyAU$630,00003 Jul 19
Hishenk Pty Ltd.
EntityCompany
Shares1,657,895
Max PriceAU$0.38
BuyAU$4,63805 Apr 19
James Garner
EntityIndividual
Role
Chief Executive Officer
CEO, MD & Executive Director
Shares10,000
Max PriceAU$0.47
BuyAU$30,77202 Apr 19
Iain Ross
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares65,527
Max PriceAU$0.47
BuyAU$4,30407 Dec 18
James Garner
EntityIndividual
Role
Chief Executive Officer
CEO, MD & Executive Director
Shares10,526
Max PriceAU$0.41
BuyAU$39,70403 Dec 18
Iain Ross
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares100,000
Max PriceAU$0.41
BuyAU$20,50013 Nov 18
Iain Ross
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares50,000
Max PriceAU$0.41
BuyAU$2,499,99926 Oct 18
Platinum Investment Management Limited
EntityCompany
Shares6,578,948
Max PriceAU$0.38
BuyAU$259,13103 Oct 18
Hishenk Pty Ltd.
EntityCompany
Shares561,743
Max PriceAU$0.47

Ownership Breakdown


Management Team

  • James Garner (46yo)

    CEO, MD & Executive Director

    • Tenure: 3.6yrs
    • Compensation: AU$691.09k
  • Kym Robins

    Director of Marketing & Communications

    • Tenure: 0yrs
  • Kate Hill (59yo)

    Company Secretary

    • Tenure: 3yrs
    • Compensation: AU$161.58k
  • Gabrielle Heaton

    Director of Finance & Administration

    • Tenure: 2.5yrs
    • Compensation: AU$237.38k

Board Members

  • Alex Matter

    Member of Scientific Advisory Board

    • Tenure: 3yrs
  • Murray Brennan (79yo)

    Member of Scientific Advisory Board

    • Tenure: 3yrs
  • Iain Ross (65yo)

    Chairman of the Board

    • Tenure: 1.7yrs
    • Compensation: AU$130.27k
  • Bryce Carmine (67yo)

    Independent Non-Executive Director

    • Tenure: 4.3yrs
    • Compensation: AU$82.13k
  • James Garner (46yo)

    CEO, MD & Executive Director

    • Tenure: 3.6yrs
    • Compensation: AU$691.09k
  • Steve Coffey

    Independent Non-Executive Director

    • Tenure: 6.8yrs
    • Compensation: AU$82.13k
  • Karen Jean Ferrante (61yo)

    Member of Scientific Advisory Board

    • Tenure: 3yrs
  • Peter Gunning

    Member of Scientific Advisory Board

    • Tenure: 3yrs
    • Compensation: AU$13.84k

Company Information

Kazia Therapeutics Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Kazia Therapeutics Limited
  • Ticker: KZA
  • Exchange: ASX
  • Founded: 1994
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$31.394m
  • Shares outstanding: 62.17m
  • Website: https://www.kaziatherapeutics.com

Location

  • Kazia Therapeutics Limited
  • Three International Towers
  • Level 24
  • Sydney
  • New South Wales
  • 2000
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NVGN.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDSep 1994
KZAASX (Australian Securities Exchange)YesOrdinary SharesAUAUDSep 1994
NV9DB (Deutsche Boerse AG)YesOrdinary SharesDEEURSep 1994
KZIANasdaqCM (Nasdaq Capital Market)SPON ADR EACH REP 10 ORD SHSUSUSDJan 1999
NV9MDB (Deutsche Boerse AG)SPON ADR EACH REP 10 ORD SHSDEEURJan 1999

Biography

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops therapies for a range of oncology indications. Its lead product is GDC-0084, a small molecule inhibitor of the PI3K / AKT / m ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/20 10:32
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.